SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Anthony@Pacific who wrote (3149)11/8/2000 6:24:38 PM
From: StockDung  Read Replies (1) of 5582
 
about what time did stockdung post?

Subject: Ride The Wave Of Fortune
Date: 3/10/98 6:41 AM Eastern Standard Time
From: Videogo
Message-id: <19980310114101.GAA03926@ladder02.news.aol.com>

Guy Quigley may have seen much of his wealth evaporate in the past month, but it's business as usual... in February he issues a 1997 financial report that most CEOs could only dream about - sales shoot through the stratosphere, climbing from $5 million in 1996 to $70 million last year. Earnings soar, beating expectations (remember, Quigley had forecast earnings of $1.32 per share, compared with 10 cents per share in 1996)... Guy beat that... making
$1.43 per share!

Not bad for a little "guy" with one product and 14 employees! Only one problem... Guy tells us that a mild winter will result in 1st quarter revenues being significantly lower than consesus, with 1998 overall revenues being affected as well.

Should we on this board forget this past year's 1,300 percent growth? Guy can't be too depressed about his wealth... two years ago, some of us on this board bought into the stock when it was trading below $1 a share!!

Keep in mind, Quigley's ZIGG lozenge continues to have higher sales in US drug stores than Halls, Ricola or Ludens. It has created an entire new category of wannabes, none of which can actually duplicate Guy's gluconate-glycine formula. Warner-Lambert's imitation "Zinc Defense" isn't even on the list of approved FDA substances to be taken internally!

Cold-Eeze may be hard pressed to maintain its 5-to-1 sales lead, but I say it's a buy at any price under 20... Our biggest test: how to sustain Wall Street's interest in a one-product firm whose revenues will rise and fall with the severity of the cold season.

Quigley shareholdres should not be chasing after the immediate profit... I'm sure Guy wouldn't mind shedding his company's reputation as a "health care tidal wave" and replacing it with the image of a good, solid investment.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext